The second report in our Deal Dimensions series, written in collaboration with Mergermarket and launched today, reveals that 94 per cent of life sciences companies are planning an acquisition in the next year, with more than two-thirds (70 per cent) of respondents targeting personalised medicine.
For many life sciences companies, acquisitions are now the preferred way to deliver the growth rates their investors have become accustomed to. M&A began gathering pace in 2014 and the trend has continued: in the first half of 2015, deal value increased 53 per cent on the same period last year and the second half of 2015 began with a burst of new transaction announcements, including Teva Pharmaceutical’s US$40.5bn purchase of the generics division of Allergan – the largest deal announced so far in 2015.
The report, entitled Life lines: Life sciences M&A and the rise of personalised medicine, explores the main drivers behind the avid pursuit of cross-border life sciences deals, the challenges faced in executing those deals, and how advances in personalised medicine may change the face of the industry.
Download the .PDF below to find out more.